HIV/AIDS

HIV/AIDS
Name	Acquired Immunodeficiency Syndrome
Field	Infectious disease
Symptoms	Opportunistic infections, weight loss, fever, night sweats
Complications	Tuberculosis, Kaposi sarcoma, lymphoma
Onset	Variable; months to years after infection
Causes	Human immunodeficiency virus
Risks	Unprotected sex, contaminated blood, needle sharing, mother-to-child transmission
Prevention	Condoms, needle exchange, pre-exposure prophylaxis, antiretroviral therapy
Medication	Antiretroviral therapy
Prognosis	Improved with early treatment
Frequency	Approximately 38 million living with infection (global estimate)

HIV/AIDS Acquired immunodeficiency syndrome is a chronic, progressive condition caused by infection with the human immunodeficiency virus. It leads to immune system deterioration and susceptibility to opportunistic infections and malignancies. Global efforts by organizations such as World Health Organization, UNAIDS, Centers for Disease Control and Prevention, Médecins Sans Frontières, and national health ministries have shaped prevention, diagnosis, and treatment strategies.

History

Early clinical descriptions resembling the syndrome appeared in medical reports and case series in the 1970s and early 1980s, noted in hospitals and clinics associated with Johns Hopkins Hospital, San Francisco General Hospital, and institutions in New York City. Epidemiological investigations linked the syndrome to transfusion programs and blood banks such as American Red Cross, prompting screening changes after discoveries at research centers including Institut Pasteur, University of California, San Francisco, and Centers for Disease Control and Prevention. The isolation of the causative virus at laboratories like Institut Pasteur and National Institutes of Health led to Nobel-recognized research trajectories and large-scale public health campaigns by World Health Organization and UNAIDS. Political and social responses involved policymakers from administrations and legislatures in countries such as the United States, South Africa, and France, and advocacy from groups including ACT UP, Elizabeth Glaser Pediatric AIDS Foundation, and community organizations that influenced funding through entities like the Global Fund and programs such as the President's Emergency Plan for AIDS Relief.

Virology and Pathogenesis

The causative agent is a lentivirus belonging to the Retroviridae family, with structural and replication features studied in laboratories at Cold Spring Harbor Laboratory, Scripps Research, and National Institutes of Health. Viral entry utilizes receptors first characterized in molecular studies at universities including Harvard University and Massachusetts Institute of Technology, where coreceptor interactions with CD4 and chemokine receptors were elucidated. Reverse transcription, integration by integrase, and viral assembly involve enzymes targeted by drug development programs at pharmaceutical companies and research institutes such as Gilead Sciences, Merck & Co., ViiV Healthcare, and academic centers like University of California, Los Angeles. Progressive depletion of CD4+ T lymphocytes, described in immunology texts from Oxford University Press and research from Rockefeller University, underpins susceptibility to opportunistic pathogens documented by specialists at Royal Free Hospital and University College London.

Transmission and Prevention

Primary transmission routes include sexual contact, parenteral exposure via contaminated syringes, and vertical transmission during pregnancy or breastfeeding documented in cohort studies at Kaiser Permanente, Makerere University, and University of Cape Town. Prevention tools—condoms promoted by UNICEF, needle-exchange programs supported by Médecins Sans Frontières, and biomedical prophylaxis such as pre-exposure prophylaxis developed in clinical trials at Fred Hutchinson Cancer Research Center—have reduced incidence in targeted populations. Blood safety measures implemented by national services like the American Red Cross and regulatory guidance from European Medicines Agency minimize transfusion risk. Mother-to-child transmission reduction protocols pioneered in collaborations involving Elizabeth Glaser Pediatric AIDS Foundation and World Health Organization informed guidelines adopted by ministries of health worldwide.

Diagnosis and Clinical Presentation

Laboratory diagnosis uses serological assays and nucleic acid tests standardized in reference labs at Centers for Disease Control and Prevention, Public Health England, and diagnostic companies including Abbott Laboratories and Roche Diagnostics. Acute infection may present with nonspecific febrile illness described in clinical series from Mayo Clinic and Cleveland Clinic, while chronic progression leads to opportunistic infections such as Pneumocystis jirovecii pneumonia, Mycobacterium tuberculosis co-infection, and malignancies including Kaposi sarcoma and non-Hodgkin lymphoma documented in oncology centers like Memorial Sloan Kettering Cancer Center.

Treatment and Management

Combination antiretroviral therapy, developed through collaborations among academic institutions, pharmaceutical firms, and public–private partnerships including Gilead Sciences, ViiV Healthcare, and Merck & Co., transformed prognosis. Regimens combine nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, and pharmacokinetic boosters; treatment guidelines are issued by professional bodies such as the World Health Organization, Department of Health and Human Services (United States), and regional societies like the European AIDS Clinical Society. Management includes monitoring at clinics affiliated with Johns Hopkins Hospital, Massachusetts General Hospital, and community health centers supported by organizations like Population Services International; adjunctive care addresses opportunistic infections, nutritional needs, and psychosocial support provided by NGOs including Treatment Action Group.

Epidemiology and Public Health Response

Global epidemiology is tracked by UNAIDS, World Health Organization, and national surveillance systems such as those run by Centers for Disease Control and Prevention and ministries of health. Epidemic patterns vary by region, with high prevalence in countries like South Africa, Botswana, and Lesotho, concentrated epidemics among key populations in cities like New York City, London, and Bangkok, and evolving incidence trends influenced by programs funded by the Global Fund and President's Emergency Plan for AIDS Relief. Public health responses combine prevention, testing, treatment scale‑up, and research networks including International AIDS Society, academic consortia at University of Cape Town, and clinical trial sites coordinated by organizations like HIV Vaccine Trials Network.

Category:Infectious diseases